Switch from Ritonavir-Boosted to Unboosted Atazanavir Guided by Therapeutic Drug Monitoring-Reference-Cited by-同舟云学术

Switch from Ritonavir-Boosted to Unboosted Atazanavir Guided by Therapeutic Drug Monitoring

Published:2008-06 Issue:6 Volume:24 Page:821-825
ISSN:0889-2229
Container-title:AIDS Research and Human Retroviruses
language:en
Short-container-title:AIDS Research and Human Retroviruses

Author:

Rodríguez-Nóvoa Sonia¹,Morello Judit¹,Barreiro Pablo²,Maida Ivana²,García-Gascó Pilar²,Vispo Eugenia²,González-Pardo Gema¹,Parra Antonio¹,Jiménez-Nácher Inmaculada¹,Soriano Vincent²

Affiliation:

1. Pharmacokinetic and Pharmacogenetic Unit, Hospital Carlos III, Madrid, Spain.

2. Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain.

Publisher

Mary Ann Liebert Inc

Subject

Infectious Diseases,Virology,Immunology

Link

http://www.liebertpub.com/doi/pdf/10.1089/aid.2007.0276

Reference20 articles.

1. Pitfalls of testing and summary of guidance on safety monitoring with amiodarone and digoxin

2. Clinical benefit of interventions driven by therapeutic drug monitoring

3. Pharmacologic Optimization of Protease Inhibitors and Nonnucleoside Reverse Transcriptase Inhibitors (POPIN)-A Randomized Controlled Trial of Therapeutic Drug Monitoring and Adherence Support

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Semi-quantification of HIV-1 protease inhibitor concentrations in clinical samples of HIV-infected patients using a gold nanoparticle-based immunochromatographic assay;Analytica Chimica Acta;2019-09

2. Abacavir/lamivudina + atazanavir no potenciado en la práctica clínica diaria: doce años de experiencia;Enfermedades Infecciosas y Microbiología Clínica;2018-01

3. Precision medicine for HIV: where are we?;Pharmacogenomics;2018-01

4. Abacavir/lamivudine + unboosted atazanavir in routine clinical practice: Twelve years experience;Enfermedades infecciosas y microbiologia clinica (English ed.);2018-01

5. Treatment response to unboosted atazanavir in combination with tenofovir disoproxil fumarate and lamivudine in human immunodeficiency virus-1-infected patients who have achieved virological suppression: A therapeutic drug monitoring and pharmacogenetic study;Journal of Microbiology, Immunology and Infection;2017-12